Veracyte said eight studies using its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology Annual Meeting in Boston from Sept. 26-30. The research includes Phase II and III trial analyses, Genomic Research for Intelligent Discovery research and national real-world studies assessing Decipher’s prognostic value and its potential to identify patients who may benefit from treatment intensification, including androgen-deprivation therapy with radiation. The presentations cover molecular subtyping, salvage radiotherapy, docetaxel, radiotherapy re-irradiation, long-term anti-androgen therapy, treatment utilization, toxicity, biochemical recurrence and secondary radiotherapy.